Last reviewed · How we verify
Mundipharma Manufacturing Pte Ltd. — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| 7.5% Povidone-Iodine [PVP-I] | 7.5% Povidone-Iodine [PVP-I] | marketed | ||||
| Normal saline gargle | Normal saline gargle | marketed | Saline rinse / Oral hygiene agent | Otolaryngology / Oral Care | ||
| Plain non antibacterial soap | Plain non antibacterial soap | marketed | Hygiene/Dermatology |
Therapeutic area mix
- Hygiene/Dermatology · 1
- Otolaryngology / Oral Care · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Mundipharma Manufacturing Pte Ltd.:
- Mundipharma Manufacturing Pte Ltd. pipeline updates — RSS
- Mundipharma Manufacturing Pte Ltd. pipeline updates — Atom
- Mundipharma Manufacturing Pte Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Mundipharma Manufacturing Pte Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mundipharma-manufacturing-pte-ltd. Accessed 2026-05-17.